Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

Cancer letters - 1 Nov 2017

Ruzzolini Jessica, Peppicelli Silvia, Andreucci Elena, Bianchini Francesca, Margheri Francesca, Laurenzana Anna, Fibbi Gabriella, Pimpinelli Nicola, Calorini Lido

Abstract excerpt

Vemurafenib, a BRAF inhibitor, elicits in ∼80% of BRAFV600E-mutant melanoma patients a transient anti-tumor response which precedes the emergence of resistance. We tested whether an acidic tumor microenvironment may favor a BRAF inhibitor resistance. A375M6 BRAFV600E melanoma cells, either exposed for a short period or chronically adapted to an acidic medium, showed traits compatible with an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelial-Mesenchymal Transition
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen-Ion Concentration

Share to Indoles

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 28826720
DOI: 10.1016/j.canlet.2017.08.010

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.PMID 28826720Read ↗

The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells.Semantic proximity Read ↗

Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation.Semantic proximity Read ↗

Acid treatment of melanoma cells selects for invasive phenotypes.Semantic proximity Read ↗

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.Semantic proximity Read ↗

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells.Semantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR ExpressionSemantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.Semantic proximity Read ↗

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblastsSemantic proximity Read ↗

An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAFV600E inhibitor-resistant metastatic melanoma cells.Semantic proximity Read ↗

The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.